@entity24174 eye-drops in XXXX or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study.

@entity1 @entity2194 @entity137 @entity24174 @entity111 @entity56
This study was carried out to assess the efficacy of 0.025% and 0.05% @entity24174 eye-drops in @entity1 with @entity56 of > or = 1 year's duration. A total of 151 @entity1 received 0.025% or 0.05% @entity24174 eye-drops or placebo b.i.d. for 14 days according to a double-blind, randomized, placebo-controlled, parallel-dosing design; 129 @entity1 completed the study as planned. The three target symptoms, scored on 4-point scales, were @entity111 , lacrimation, and @entity2194 ; responders were @entity1 whose symptom sum score decreased by > or = 3 from a baseline score of > or = 6 by day 3. Mean scores of these and five other symptoms were recorded also on days 7 and 14, and @entity1 kept daily diaries of the three main symptoms and swollen eyelids. Responder rates were 73% for 0.025% (P=0.115 vs placebo) and 82% for 0.05% @entity24174 eye-drops (P=0.011 vs placebo) and 56% for placebo. The time courses of the mean (investigators' and @entity1 ') scores for the three main symptoms reflected the dose-dependent effect of @entity24174 eye-drops. One @entity1 each from the two @entity24174 groups and three from the placebo group withdrew because of inefficacy. @entity137 were reported by 14 and 24 @entity1 receiving 0.025% and 0.05% @entity24174 eye-drops, respectively, and by eight placebo @entity1 . These reactions were mainly slight application site reactions and taste perversion (bitter or unpleasant taste). @entity24174 eye-drops are effective and well tolerated at a dose of 0.05% for the treatment of @entity56 .
